Mechanisms of Chemotherapy-Induced Peripheral Neuropathy.
Renata Zajączkowska,Magdalena Kocot-Kępska,Wojciech Leppert,Anna Wrzosek,Joanna Mika,Jerzy Wordliczek +5 more
Reads0
Chats0
TLDR
A better understanding of the risk factors and underlying mechanisms of CIPN is needed to develop effective preventive and therapeutic strategies and the neurotoxicity mechanisms of the most common antineoplastic agents are reviewed.Abstract:
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side effects caused by antineoplastic agents, with a prevalence from 19% to over 85%. Clinically, CIPN is a mostly sensory neuropathy that may be accompanied by motor and autonomic changes of varying intensity and duration. Due to its high prevalence among cancer patients, CIPN constitutes a major problem for both cancer patients and survivors as well as for their health care providers, especially because, at the moment, there is no single effective method of preventing CIPN; moreover, the possibilities of treating this syndrome are very limited. There are six main substance groups that cause damage to peripheral sensory, motor and autonomic neurons, which result in the development of CIPN: platinum-based antineoplastic agents, vinca alkaloids, epothilones (ixabepilone), taxanes, proteasome inhibitors (bortezomib) and immunomodulatory drugs (thalidomide). Among them, the most neurotoxic are platinum-based agents, taxanes, ixabepilone and thalidomide; other less neurotoxic but also commonly used drugs are bortezomib and vinca alkaloids. This paper reviews the clinical picture of CIPN and the neurotoxicity mechanisms of the most common antineoplastic agents. A better understanding of the risk factors and underlying mechanisms of CIPN is needed to develop effective preventive and therapeutic strategies.read more
Citations
More filters
Journal ArticleDOI
Axonal Endoplasmic Reticulum Dynamics and Its Roles in Neurodegeneration.
TL;DR: The transport processes that must contribute to this dynamic behavior of endoplasmic reticulum are discussed, and the model that these processes underpin a homeostatic process that ensures both enough ER to maintain continuity of the network and repair breaks in it is discussed.
Journal ArticleDOI
Neuroinflammatory Process Involved in Different Preclinical Models of Chemotherapy-Induced Peripheral Neuropathy.
TL;DR: In this article, the authors considered different aspects of neuro-immune interactions in several CIPN preclinical studies which suggest a critical connection between chemotherapeutic agents and neurotoxicity.
Journal ArticleDOI
Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment
Jamie Burgess,Maryam Ferdousi,David Gosal,Cheng Boon,Kohei Matsumoto,Anne Marshall,Tony Mak,Andrew Marshall,Andrew Marshall,Bernhard Frank,Rayaz A. Malik,Rayaz A. Malik,Uazman Alam,Uazman Alam +13 more
TL;DR: A recent review as mentioned in this paper provides an update on the current clinical, epidemiological and pathophysiological evidence alongside the diagnostic, prevention and treatment approach to chemotherapy-induced peripheral neuropathy (CIPN).
Journal ArticleDOI
Pharmacological Treatment of Chemotherapy-Induced Neuropathic Pain: PPARγ Agonists as a Promising Tool
Nara Lins Meira Quintão,José Roberto Santin,Luis Carlos Stoeberl,Thiago Patrício Corrêa,Jéssica Melato,Robson Costa,Robson Costa +6 more
TL;DR: The effects of PPARγ agonists, known for their positive activity on type II diabetes mellitus, have been explored and present promising effects in the control of neuropathic pain, including CINP, and also cancer.
Journal ArticleDOI
Vinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: From pathogenesis to treatment
TL;DR: This review critically examines the pathogenesis, epidemiology, risk factors (both clinical and pharmacogenetic), clinical phenotype and management of CIPN as a result of exposure to vinca alkaloids, thalidomide and its analogue lenalidomides as also eribulin.
References
More filters
Journal ArticleDOI
Metals, toxicity and oxidative stress.
TL;DR: This review summarizes recent findings in the metal-induced formation of free radicals and the role of oxidative stress in the carcinogenicity and toxicity of metals.
Journal ArticleDOI
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
A. de Gramont,A. Figer,M. Seymour,M. Homerin,A. Hmissi,J. Cassidy,Corrado Boni,H. Cortes-Funes,Andrés Cervantes,Gilles Freyer,Demetris Papamichael,N. Le Bail,C. Louvet,D. Hendler,F. de Braud,C. Wilson,Francois Morvan,Andrea Bonetti +17 more
TL;DR: The LV5FU2-oxaliplatin combination seems beneficial as first-line therapy in advanced colorectal cancer, demonstrating a prolonged progression-free survival with acceptable tolerability and maintenance of QoL.
Journal ArticleDOI
Cisplatin in cancer therapy: molecular mechanisms of action
Shaloam Dasari,Paul B. Tchounwou +1 more
TL;DR: This comprehensive review highlights the physicochemical properties of cisplatin and related platinum-based drugs, and discusses its uses (either alone or in combination with other drugs) for the treatment of various human cancers.
Journal ArticleDOI
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
Dawn L. Hershman,Christina Lacchetti,Robert H. Dworkin,Ellen M. Lavoie Smith,Jonathan Bleeker,Guido Cavaletti,Cynthia Chauhan,Patrick Gavin,Antoinette Lavino,Maryam B. Lustberg,Judith A. Paice,Bryan P. Schneider,Mary Lou Smith,Thomas J. Smith,Shelby A. Terstriep,Nina D. Wagner-Johnston,Kate Bak,Charles L. Loprinzi +17 more
TL;DR: Although the CIPN trials are inconclusive regarding tricyclic antidepressants (such as nortriptyline), gabapentin, and a compounded topical gel containing baclofen, amitriptylines HCL, and ketamine, these agents may be offered on the basis of data supporting their utility in other neuropathic pain conditions given the limited other CIPn treatment options.
Journal ArticleDOI
Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis.
Marta Seretny,Gillian L. Currie,Emily S. Sena,Sabrina Ramnarine,Robin Grant,Malcolm R. Macleod,Leslie A. Colvin,Marie Fallon +7 more
TL;DR: A systematic review of studies reporting the prevalence of Chemotherapy‐induced peripheral neuropathy identified 31 studies with data from 4179 patients and identified a number of genetic and clinical risk factors that require further study.
Related Papers (5)
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
Dawn L. Hershman,Christina Lacchetti,Robert H. Dworkin,Ellen M. Lavoie Smith,Jonathan Bleeker,Guido Cavaletti,Cynthia Chauhan,Patrick Gavin,Antoinette Lavino,Maryam B. Lustberg,Judith A. Paice,Bryan P. Schneider,Mary Lou Smith,Thomas J. Smith,Shelby A. Terstriep,Nina D. Wagner-Johnston,Kate Bak,Charles L. Loprinzi +17 more